Flatiron Health has launched six new hematology-focused Panoramic datasets powered by artificial intelligence, marking a major advancement in real-world evidence for blood cancers. The new datasets, which include five B-cell lymphoma subtypes and multiple myeloma, are built from over 505,000 longitudinal patient records across Flatiron’s network—representing a sixfold increase in cohort size compared to previous offerings. These datasets leverage Flatiron’s AI-enabled large language models and its rigorous VALID data quality framework to extract and validate clinical information at scale. The result is highly detailed, longitudinal data capturing rich clinical insights, including molecular residual disease (MRD) testing and CAR-T therapy utilization—key factors in modern hematology treatment and outcomes. The expansion builds on Flatiron’s decade-long effort to create one of the world’s most comprehensive real-world oncology databases, now encompassing over five million patient records and more than 1.5 billion data points. The new hematology datasets offer enhanced clinical breadth and depth, enabling researchers and life science companies to study rare patient populations and niche subgroups that have historically been underrepresented in clinical research. Nathan Hubbard, CEO of Flatiron Health, emphasized the transformative potential of combining AI with scientific rigor. “These datasets showcase what becomes possible when you merge proven AI capabilities with a commitment to data quality—unlocking the potential for more precise, personalized treatments for patients with hematologic malignancies.” Kate Estep, VP and Head of Product, highlighted the datasets’ ability to support complex research needs, such as evaluating novel therapies, molecular response patterns, and treatment adherence. “We’re not just delivering more data—we’re delivering the right data at the scale researchers need, while maintaining the gold-standard quality that regulatory and clinical partners rely on.” Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology, noted the datasets reflect the rapid evolution of hematology care, including breakthroughs in immunotherapies like CAR-T and bispecifics, targeted agents like menin inhibitors, and ultra-sensitive monitoring tools like MRD testing. “These datasets capture the true complexity of modern treatment patterns at a scale that wasn’t possible before—transforming how we understand and improve care for blood cancer patients.” Flatiron’s deep hematology expertise, combined with in-house analytics and medical teams, supports previously unattainable analyses. The company has over 250 publications in blood cancer research and more than 275 research presentations accepted at leading scientific conferences in 2025, including ISPOR Europe and the upcoming ASH 2025 meeting. Panoramic data, Flatiron’s core real-world data platform, is designed to meet the evolving needs of biopharma, offering biomarker depth, longitudinal tracking, and scalable outcomes across more than 5 million patients. The new hematology datasets are part of a broader effort to accelerate research, support drug development, and improve patient outcomes in oncology. Flatiron Health, an independent affiliate of the Roche Group, continues to advance a connected, data-driven future for cancer care.